DUBLIN–()–The “Fibromyalgia (Fibromyalgia Syndrome) – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s providing.

Fibromyalgia – Pipeline Review, H2 2020, supplies complete info on the therapeutics beneath growth for Fibromyalgia (Central Nervous System), full with evaluation by stage of growth, drug goal, mechanism of motion (MoA), route of administration (RoA) and molecule sort. The information covers the descriptive pharmacological motion of the therapeutics, its full analysis and growth historical past and newest information and press releases.

The Fibromyalgia (Central Nervous System) pipeline information additionally evaluations of key gamers concerned in therapeutic growth for Fibromyalgia (Fibromyalgia Syndrome) and options dormant and discontinued initiatives. The information covers therapeutics beneath Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery levels are 3, 4, 8, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical levels includes 1 and 1 molecules, respectively.

Fibromyalgia (Central Nervous System) pipeline information helps in figuring out and monitoring rising gamers available in the market and their portfolios, enhances determination making capabilities and helps to create efficient counter methods to realize aggressive benefit.


  • The pipeline information supplies a snapshot of the worldwide therapeutic panorama of Fibromyalgia (Central Nervous System).
  • The pipeline information evaluations pipeline therapeutics for Fibromyalgia (Central Nervous System) by corporations and universities/analysis institutes based mostly on info derived from firm and trade-particular sources.
  • The pipeline information covers pipeline merchandise based mostly on a number of levels of growth starting from pre-registration until discovery and undisclosed levels.
  • The pipeline information options descriptive drug profiles for the pipeline merchandise which comprise, product description, descriptive licensing and collaboration particulars, R&D transient, MoA & different developmental actions.
  • The pipeline information evaluations key corporations concerned in Fibromyalgia (Central Nervous System) therapeutics and enlists all their main and minor initiatives.
  • The pipeline information evaluates Fibromyalgia (Central Nervous System) therapeutics based mostly on mechanism of motion (MoA), drug goal, route of administration (RoA) and molecule sort.
  • The pipeline information encapsulates all of the dormant and discontinued pipeline initiatives.
  • The pipeline information evaluations newest information associated to pipeline therapeutics for Fibromyalgia (Central Nervous System)

Key Topics Covered:


Fibromyalgia (Fibromyalgia Syndrome) – Overview

Fibromyalgia (Fibromyalgia Syndrome) – Therapeutics Development

Fibromyalgia (Fibromyalgia Syndrome) – Therapeutics Assessment

Fibromyalgia (Fibromyalgia Syndrome) – Companies Involved in Therapeutics Development

Fibromyalgia (Fibromyalgia Syndrome) – Drug Profiles

Fibromyalgia (Fibromyalgia Syndrome) – Dormant Projects

Fibromyalgia (Fibromyalgia Syndrome) – Discontinued Products

Fibromyalgia (Fibromyalgia Syndrome) – Product Development Milestones


Companies Mentioned

  • Aptinyx Inc
  • Cortene Inc
  • Cytocom Inc
  • Epitech Group SpA
  • H. Lundbeck AS
  • Imbrium Therapeutics LP
  • Innovative Med Concepts LLC
  • Intec Pharma Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Luye Pharma Group Ltd
  • NeuroCycle Therapeutics Inc
  • One World Cannabis Ltd
  • Pfizer Inc
  • PRISM Pharma Co Ltd
  • Reven Pharmaceuticals Inc
  • Tetra Bio-Pharma Inc
  • Teva Pharmaceutical Industries Ltd
  • Tonix Pharmaceuticals Holding Corp

For extra details about this drug pipelines report go to https://www.researchandmarkets.com/r/1jis7h

Source link